RYTELO Fact Sheet
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor used to treat adults with IPSS-R low to intermediate-1 myelodysplastic syndromes (MDS) with transfusion dependent anemia requiring four or more red blood…
Please make a donation to the Aplastic Anemia and MDS International Foundation.
Donate Today
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor used to treat adults with IPSS-R low to intermediate-1 myelodysplastic syndromes (MDS) with transfusion dependent anemia requiring four or more red blood…
TIBSOVO is a prescribed medication approved to treat adult patients with myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation either when the disease has relapsed or has not improved after…
REBLOZYL® (luspatercept-aamt) was the first erythroid maturation agent (EMA) approved in 2020 by the Food and Drug Administration for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who…
INQOVI® (previously known as ASTX727) is a prescribed oral tablet combination of decitabine and cedazuridine approved by the Food and Drug Administration for adult patients with myelodysplastic syndromes (MDS) and…
Form to keep track of platelet transfusions as part of MDS treatment
Form to keep track of blood transfusions as part of MDS treatment
Chart to record medical professionals, pharmacy contacts, patient support organizations and others involved with your health care
Form to record symptoms or reactions to treatment and medications that can be shared with health care providers
Form to record health care visits and notes
Use the AAMDS Map of Specialists to find an MDS expert